DDAH1 and prostate carcinoma: Mir-193b has been previously reported as a tumor suppressor in breast cancer tissues (209, 210) and is frequently downregulated in other solid tumors such as melanoma (211), liver cancer (212), and prostate cancer (213), all of which are reported to exhibit increased DDAH1 expression (Table 1).